Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- AI-Driven Innovation Reshapes Vaccine Adjuvant Discovery as Investment Surges Across Public and Private Sectors“AI is bringing greater speed and precision to vaccine adjuvant research, helping advance smarter formulations and next-generation vaccines.”
- NVIDIAHow Open Science Can Help Researchers Prepare for the Next PandemicCompanies: NvidiaWhen COVID-19 emerged, scientists had a crucial advantage: Decades of prior research on coronaviruses meant they understood the virus’ key proteins well enough to design vaccines in record time. The next pandemic may not offer the same head start. To help improve the odds, NVIDIA has joined a coalition of global research organizations, including Google […]
- Anavex Stockholders Elect All of the Company’s Director Nominees at 2026 Annual MeetingAnavex Life Sciences Corp. (“Anavex” or the “Company”), a clinical-stage biopharmaceutical company focused on developing innovative treatments for central nervous system diseases with high unmet medical needs, today announced that, based on the preliminary vote count provided by its proxy solicitor following the Company’s 2026 Annual Meeting of Stockholders (“Annual Meeting”), Anavex stockholders have voted to elect all six of its director nominees – Dr. Jiong Ma, Dr. Peter Donhauser, Dr. Axel Paeger, Mr. Gautam Patel, Dr. Adrian Senderowicz and Dr. Claus van der Velden.
- BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), Lantheus Holdings Inc. (Nasdaq – LNTH), MarketAxess Holdings Inc. (Nasdaq – MKTX)Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot UlcersInitiation of patient dosing marks significant clinical development milestone for Nu-3 and Lakewood-Amedex Biotherapeutics' proprietary Bisphosphocin® antimicrobial platform Topline data expected in the first quarter of 2027 SARASOTA, Fla., Sept. 24, 2026 -- Lakewood-Amedex...
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for EndometriosisPhase 2 trial to assess efficacy and safety in participants with surgically-diagnosed endometriosis and moderate to severe endometriosis-associated pain (EAP)
- Milestone Pharmaceuticals Inc. MONTREAL andMilestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVRMontreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of Etripamil
- Lupus Nephritis Pipeline 2026: Targeted Therapies and Clinical Innovation Drive New Treatment and Market Opportunities Through the Forecast PeriodLupus nephritis R&D is shifting toward targeted B-cell, complement, and off-the-shelf cell therapies, opening partnership and licensing opportunities across novel treatment platforms
- Oncology Clinical Trials Market Set for Strong Growth Through 2035, Fueled by Precision Medicine, Immunotherapy and Decentralized Trial InnovationRising cancer incidence and R&D investment are expanding oncology trials. AI can improve recruitment, trial design and data management, while partnerships and novel therapies spur competition.
- Cytokine Release Syndrome Market Set for Growth Through 2036 as Rising Incidence and Treatment Innovation Drive New OpportunitiesExpanding CAR-T and bispecific use is increasing CRS cases, creating opportunities in early diagnosis, preventive immunomodulators, outpatient care and biosimilar IL-6 therapies.
- Post-Operative Pain Management Market Set for Growth Through 2036 as Rising Surgical Volumes and Innovative Therapies Drive New OpportunitiesRising surgeries and opioid safety concerns are accelerating multimodal, non-opioid pain care, creating opportunities for safer parenteral drugs and novel delivery systems.
- AI in Life Sciences Market to Reach US$11.52 Billion by 2034 as Drug Discovery, Precision Medicine and Automation Drive New Business OpportunitiesAI adoption is accelerating drug discovery, precision medicine, diagnostics and clinical trials, fueled by expanding health data, software demand and pharma-tech partnerships